Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch

Investing.comOct 31, 2024 3:14 PM

View all comments（0）



Investing.com -- Biogen (NASDAQ:BIIB) shares slid around 3% Thursday after Morgan Stanley (NYSE:MS) analysts downgraded the stock from Overweight to Equal Weight and slashed the price target from $285 to $204.

The revision comes as the launch of Biogen's Alzheimer's drug Leqembi has fallen short of expectations. As a result, Morgan Stanley has trimmed its 2024 and beyond revenue estimates for Leqembi by 50%, now projecting worldwide sales of $2.4 billion in 2033, down from the prior estimate of $5.6 billion.

The firm also noted that the growth forecast for 2025 to 2030 has been adjusted to 1% from 4%.

Analysts said they have underestimated the initial reimbursement and logistical headwinds, compounded by the postponement of the subcutaneous formulation of Leqembi, which offers more convenient dosing than the current schedule.

Moreover, a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) has impacted prospects.

They also cited potential near-term challenges from the launch of Eli Lilly (NYSE:LLY)'s Alzheimer's drug Kisunla.

“While we acknowledge we could be downgrading the stock at/near the bottom, we struggle to see an upside path over the next 12 months,” analysts led by Terence C Flynn said in a note.

Still, they acknowledged potential upside drivers for Biogen shares, including the Alzheimer's prevention opportunity with the ongoing Leqembi Phase 3 AHEAD-3-45 trial, Phase 2 data for BIIB080 in Alzheimer's, and the progression of Felzartamab into Phase 3 trials.

Biogen’s management has highlighted ongoing expansion in Leqembi prescribers and early signs of U.S. market acceleration. In Japan, the revenue for Leqembi nearly doubled quarter over quarter.

Regulatory actions for the subcutaneous formulation are expected in mid-2025 and the first quarter of 2026. Despite these developments, Morgan Stanley sees a low likelihood of approval for Leqembi by the European Medicines Agency (EMA) following the CHMP re-examination due this year.

Morgan Stanley also outlined potential risks and opportunities for BIIB. Upside risks include significant Alzheimer's market growth, better-than-expected Leqembi data, and pipeline outperformance.

On the other hand, downside risks involve stronger competition from Kisunla, pipeline failures or delays, and inefficient capital use.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Today’s Market Recap: Broadcom and Nvidia Lead Tech Gains, Oil Prices Surge, Gold Under Pressure

TradingKey - On July 8, Eastern Time, US stocks showed divergent performance. Escalating conflicts between the US and Iran pushed energy prices back up, fueling market concerns over sticky inflation and the Federal Reserve's policy path, which dragged down the Dow Jones Industrial Average and the S&

NVIDIA (NVDA) Stock Forecast: DeepSeek Building Its Own Chip - Is $197 the Bottom?

Reuters says DeepSeek is building its own AI chip to cut ties with Nvidia. NVDA slipped 2% on the news but still holds $197. The chart has flipped to a long setup. 61 analysts Buy at $301 avg target.

Japan and South Korea Stocks Surge at Open: Nikkei 225 and Kospi Soar Together, SK Hynix and Kioxia Jump 8%, Samsung and SoftBank Follow

Japanese and South Korean stock markets opened higher and continued to rise, with the KOSPI Index and the Nikkei 225 index gaining to varying degrees. SK Hynix and Kioxia surged by approximately 8%, while Samsung Electronics and SoftBank tracked the gains.

US Stocks Close: Dow Plunges 1.09%, Nasdaq Rises Against Trend, Philadelphia Semiconductor Index Gains Over 2%; Trump Announces End of US-Iran Ceasefire Agreement, Some Fed Officials See Need for Rate Hike.

TradingKey - Donald Trump publicly stated that he has no intention of resuming any agreement negotiations with Iran, dampening market trading sentiment. The three major US stock indexes diverged, with the Dow Jones Industrial Average taking a hit, the Nasdaq Composite rising, blue-chip stocks declining, and memory chip stocks rebounding. At the close, the Dow Jones Industrial Average fell 1.09% to 52,348.39 points; the Nasdaq Composite Index rose 0.20% to 25,870.65 points; and the S&P 500 Index fell 0.28% to 7,482.71 points.

FOMC Minutes: Fed Shifts to Neutral Wait-and-See Stance, a Few Officials See Need to Raise Rates, Upside Inflation Risks Become Core Conflict

The Federal Reserve released the minutes of its June 16-17 FOMC monetary policy meeting on July 8. The document shows that the Fed's policy has completely shifted to a neutral, wait-and-see stance, with upside risks to inflation becoming the core contradiction. This FOMC meeting sent a clear signal that the Fed has completely moved away from its previous unilateral rate-cut bias and entered a period of two-way, flexible policy observation. Higher-than-expected inflation stickiness and its broadening scope are the core reasons for this policy shift, while the resilience of employment and growth provides room for flexible policy adjustments. Officials confirmed a further rise in inflation, noting that pressures are no longer confined to exogenous factors such as energy and tariffs. Instead, price increases have spread across a wide range of categories including transportation, airfares, and oil, with service inflation excluding housing showing almost no improvement. In the short term, as shipping through the Strait of Hormuz recovers and the marginal effects of tariffs fade, inflation is expected to decline gradually.

Featured Tools